Literature DB >> 12208466

Combined effects of cholesterol reduction and apolipoprotein A-I expression on atherosclerosis in LDL receptor deficient mice.

Masa-aki Kawashiri1, YuZhen Zhang, Ellen Puré, Daniel J Rader.   

Abstract

Reduction of total and LDL cholesterol reduces atherosclerosis and clinical cardiovascular events. High density lipoprotein (HDL) cholesterol levels have a strong inverse association with atherosclerosis, and overexpression of apolipoprotein A-I (apoA-I), the major protein component of HDL, reduces atherosclerosis in hypercholesterolemic animals. However, little is known about the potential for additive or synergistic effects between cholesterol reduction and apoA-I overexpression on atherosclerosis. In the current study, we tested the hypothesis that significant reduction of plasma cholesterol combined with overexpression of apoA-I would reduce atherosclerosis to a greater extent than either one alone. We used somatic gene transfer of the LDL receptor (to induce cholesterol reduction) and apoA-I in LDL receptor deficient mice fed a Western type diet and compared the combination to expression of each gene alone and to controls. Atherosclerosis was quantitated using two independent methods, by en face analysis of the entire aorta and by cross-sectional analysis of the aortic root. Although the reduction of cholesterol was transient, expression of the LDL receptor alone significantly reduced atherosclerosis by 45% in the aorta and 44% in the aortic root compared with controls. Overexpression of human apoA-I alone reduced atherosclerosis by 42% in the aorta and 44% in the aortic root compared with controls. Co-expression of the LDL receptor with apoA-I resulted in significantly higher levels of apoA-I than expression of apoA-I alone. Although co-expression of the LDL receptor and apoA-I reduced atherosclerosis by 37% in the aorta and 32% in the aortic root compared with controls, the reduction in atherosclerosis was no different than that seen with expression of the LDL receptor alone or apoA-I alone. In summary, in this relatively short-term murine model, simultaneous reduction of cholesterol and expression of apoA-I was associated with higher levels of apoA-I than expression of apoA-I alone but did not result in greater reduction in atherosclerosis compared with either one alone.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208466     DOI: 10.1016/s0021-9150(02)00103-x

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  10 in total

Review 1.  Liver-directed gene therapy for dyslipidemia and diabetes.

Authors:  Kazuhiro Oka; Lawrence Chan
Journal:  Curr Atheroscler Rep       Date:  2004-05       Impact factor: 5.113

2.  Bone marrow transplantation shows superior atheroprotective effects of gene therapy with apolipoprotein A-I Milano compared with wild-type apolipoprotein A-I in hyperlipidemic mice.

Authors:  Lai Wang; Behrooz G Sharifi; Theresa Pan; Lei Song; Ada Yukht; Prediman K Shah
Journal:  J Am Coll Cardiol       Date:  2006-08-28       Impact factor: 24.094

3.  5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.

Authors:  Marcelo J A Amar; Wilissa D'Souza; Scott Turner; Stephen Demosky; Denis Sviridov; John Stonik; Jayraz Luchoomun; Jason Voogt; Marc Hellerstein; Dmitri Sviridov; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2010-05-19       Impact factor: 4.030

4.  Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteins.

Authors:  Giorgio Cavigiolio; Ethan G Geier; Baohai Shao; Jay W Heinecke; Michael N Oda
Journal:  J Biol Chem       Date:  2010-04-12       Impact factor: 5.157

Review 5.  Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects.

Authors:  Masa-aki Kawashiri; Kenshi Hayashi; Tetsuo Konno; Noboru Fujino; Hidekazu Ino; Masakazu Yamagishi
Journal:  Heart Vessels       Date:  2013-08-02       Impact factor: 2.037

6.  High yield expression and purification of recombinant human apolipoprotein A-II in Escherichia coli.

Authors:  Loren E Smith; Jun Yang; Leah Goodman; Xinqi Huang; Rong Huang; James Dressman; Jamie Morris; R A Gangani D Silva; W Sean Davidson; Giorgio Cavigiolio
Journal:  J Lipid Res       Date:  2012-05-25       Impact factor: 5.922

Review 7.  Inhibition and regression of atherosclerotic lesions.

Authors:  Kazuhiro Oka; Lawrence Chan
Journal:  Acta Biochim Pol       Date:  2005-06-03       Impact factor: 2.149

8.  A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice.

Authors:  John K Bielicki; Haiyan Zhang; Yuan Cortez; Ying Zheng; Vasanthy Narayanaswami; Arti Patel; Jan Johansson; Salman Azhar
Journal:  J Lipid Res       Date:  2010-01-14       Impact factor: 5.922

9.  Induction of fatal inflammation in LDL receptor and ApoA-I double-knockout mice fed dietary fat and cholesterol.

Authors:  Manal Zabalawi; Shaila Bhat; Tara Loughlin; Michael J Thomas; Eric Alexander; Mark Cline; Bill Bullock; Mark Willingham; Mary G Sorci-Thomas
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

10.  Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease.

Authors:  Alex E Roher; Chera L Maarouf; Lucia I Sue; Yiran Hu; Jeffrey Wilson; Thomas G Beach
Journal:  Biomarkers       Date:  2009-11       Impact factor: 2.658

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.